Recent approaches to improve the treatment of KSHV-associated B-cell disorders have focused on MYC (v-myc myelocytomatosis viral oncogene homolog) as a molecular target.11 MYC is also involved in the natural history of MCD-DLBCL and PEL; for example, by regulating KSHV's latent and lytic life cycles.12 On this backdrop, we decided to investigate whether vIL-6 collaborates with deregulated Myc in lymphoma development in mice. Here, MYC is linked to primary effusion lymphoma.